Patient Information: The Future of Tumor Ablation Therapies
RFA and other tumor ablation therapies are already widely used to treat liver tumors and to eliminate painful bone tumors. RFA treatment of liver tumors has been approved by the FDA for almost a decade, and some researchers recommend that RFA be the first-line treatment for tumors in that organ.
Researchers are currently studying the use of RFA and other tumor ablation methods for the following areas:
• Kidney
• Lung
• Breast
• Prostate
• Adrenal glands
The National Institutes of Health is conducting studies on RFA for the treatment of liver and kidney tumors and is also testing the efficacy of different equipment.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
